Combination Therapy for Hypervirulent Klebsiella Pneumoniae

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for treating hypervirulent Klebsiella pneumoniae infections are inadequate in a subject.

Innovation Solution

Current methods for treating hypervirulent Klebsiella pneumoniae infections are inadequate in a hypervirulent Klebsiella pneumoniae subjects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional antibiotic therapy is used for hvKp infection, then bacterial infection is treated, but multidrug resistance and high mortality rates occur

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidmortality rate

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent combines antibiotic therapy with immunosuppressive agents (steroids or JAK inhibitors) into a composite treatment regimen. This merging of antimicrobial and immunomodulatory therapies addresses both the bacterial infection and the harmful cytokine storm response, thereby reducing mortality while maintaining treatment effectiveness against multidrug-resistant hvKp strains.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent changes the therapeutic parameter by introducing immunosuppressive agents that modulate the host immune response. Specifically, steroids or JAK inhibitors are administered to suppress excessive cytokine production, transforming the treatment approach from purely antimicrobial to a combination that controls both bacterial load and host response intensity.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If host immune response is fully activated to clear Kp, then infection is controlled, but cytokine storm and immune-mediated damage occur

Engineering Contradiction:

Improveinfection clearanceVSAvoidcytokine storm

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful cytokine storm into a beneficial controlled immune response by selectively suppressing excessive cytokine production. Immunosuppressive agents are used to dampen the hyperactive immune response that causes tissue damage, while maintaining sufficient immunity to clear the infection. This transforms the harmful uncontrolled cytokine release into a controlled, therapeutic immune response.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent applies partial suppression of the immune response rather than complete inhibition. By using immunosuppressive agents at controlled doses, the treatment selectively dampens excessive cytokine production that causes harm, while preserving enough immune functionality to effectively clear the hvKp infection. This partial action approach avoids complete immunosuppression while still preventing cytokine storm.

Inventive Principle:

Principle #16Partial or excessive action

Data Source

PatentUS12622919B2Methods for treating hypervirulent <i>Klebsiella pneumoniae </i>infection

Publication Date: 2026.05.12 CITY UNIVERSITY OF HONG KONG

AI summary

Methods of treating a hypervirulent Klebsiella pneumoniae (hvKp) infection in a subject in need thereof, the method involving co-administering a therapeutically effective amount of an antibiotic and a non-steroidal anti-inflammatory drug or a signal transducer and activator of transcription 1 inhibitor to the subject.